Silibinin inhibits angiogenesis via Flt-1, but not KDR, receptor up-regulation.
BACKGROUND
Our previous study found that silymarin (SM) and its major pure component silibinin (SB) have anti-angiogenic effects via decreased vascular endothelium growth factor (VEGF) secretion of LoVo cells (colon cancer). We designed this consecutive study to evaluate the anti-angiogenic effects of SM/SB in vivo, and on VEGF receptor (VEGFR) gene expression.


METHODS
We used LoVo cells exposed to SM/SB in a modified chicken chorioallantoic membrane assay (CAM) to evaluate anti-angiogenic effects. We used EA.hy 926 cells (endothelial cells) exposed to SM/SB to evaluate the effect on VEGFR-1 (Flt-1) and VEGFR-2 (KDR), with 1-step, real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR).


RESULTS
In CAM, SM/SB showed a dose-dependent decrease on the vascular density index (VDI) induced by LoVo cells, as did thalidomide in a concentration of 10 microg/ml. Adding escalating dosages of VEGF successfully reversed this inhibitory effect. RT-PCR revealed that SB up-regulated Flt-1 mRNA expression of EA.hy 926 cells. SM had a similar trend, although the effect was not statistically significant (P = 0.19). Neither drug effected KDR mRNA expression.


CONCLUSIONS
We conclude that anti-angiogenic effects of SM/SB are associated with the up-regulation of VEGFR-1 (Flt-1) gene expression and that they are good candidates for combination therapy to treat colorectal cancer.
Yang
Shung-Haur
SH
Institute of Clinical, Taipei, Taiwan, ROC.
Lin
Jen-Kou
JK
Huang
Chi-Jung
CJ
Chen
Wei-Shone
WS
Li
Shih-Yun
SY
Chiu
Jen-Hwey
JH
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D002460:Cell Line; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms; D042783:Endothelial Cells / Q000187:drug effects; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D000077385:Silybin; D012838:Silymarin / Q000494:pharmacology; D015854:Up-Regulation; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000235:genetics*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics*
D020533:Angiogenesis Inhibitors; D012838:Silymarin; D000077385:Silybin; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2